Article
IL-17 serum levels in psoriatic arthritis: Is there a correlation in early stages of freshly diagnosed Psoriasis Arthritis?
Search Medline for
Authors
Published: | February 5, 2019 |
---|
Outline
Text
Background: Psoriasis (PsO) is a chronic inflammatory disease associated with other systemic disorders like cardiovascular diseases, metabolic syndromes and arthritis associated with tendonitis. Previously we could demonstrate in freshly diagnosed psoriatic patients Ultrasonic (US) and/or power doppler (PD)abnormaitiesin the flexor tendons of the feet in 70% of the patients [1].
It is well known that in the pathogenesis of PSO and>PSA the IL-17 pro-imflammatory cytokine pathway plays an important role.
We studied the IL-17 levels in our cohort of early psoriatic arthritis patients.
Methods: We measured the IL-17 levels by Enzyme-Linked Immunoabsorbant Assay (ELISA) in PsO-patients of our cohort and analyzed the correlation in relation to clinical parameters, assessments (PASI, DLQI) classification criteria (Caspar, Gepard) and US PD results.
Results: 49 patients of our cohort of 51 patients with freshly diagnosed psoriasis with 70% of pathological US and PD results of the flexor tendons of the feet could be analyzed. There was a range in IL-17 levels from 0-771.
No statistically significance could be seen in relation to clinical parameters, Classification Criteria levels,PASI,DLQI or enthesitis disease activity measured by ultrasonic and powerdoppler signals in the flexor tendons of the feet or the Achilles tendons.
Conclusion: In our cohort of very early psoriatic arthrits the IL-17 level is not correlated with disease activity.